Ugurel S - Search Results

1

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.

Placke JM, Soun C, Bottek J, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Pfeiffer C, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Zimmer L, Livingstone E, Becker JC, Lodde G, Sucker A, Griewank K, Horn S, Hadaschik E, Roesch A, Schadendorf D, Engel DR, Ugurel S. Placke JM, et al. Among authors: ugurel s. Front Oncol. 2021 Sep 21;11:741993. doi: 10.3389/fonc.2021.741993. eCollection 2021. Front Oncol. 2021. PMID: 34621681 Free PMC article.

2

Successful treatment of progressive vitiligo with high-dose intravenous methylprednisolone 'pulse' therapy.

Seiter S, Ugurel S, Pföhler C, Tilgen W, Reinhold U. Seiter S, et al. Among authors: ugurel s. Dermatology. 1999;199(3):261-2. doi: 10.1159/000018260. Dermatology. 1999. PMID: 10592410

3

Interferon-alpha-associated development of bullous lesions in mycosis fungoides.

Pföhler C, Ugurel S, Seiter S, Wagner A, Tilgen W, Reinhold U. Pföhler C, et al. Among authors: ugurel s. Dermatology. 2000;200(1):51-3. doi: 10.1159/000018317. Dermatology. 2000. PMID: 10681616

4

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).

Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W. Hauschild A, et al. Among authors: ugurel s. Br J Cancer. 2001 Apr 20;84(8):1036-42. doi: 10.1054/bjoc.2001.1731. Br J Cancer. 2001. PMID: 11308250 Free PMC article. Clinical Trial.

5

Dose-dependent severe cutaneous reactions to imatinib.

Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Ugurel S, et al. Br J Cancer. 2003 Apr 22;88(8):1157-9. doi: 10.1038/sj.bjc.6600893. Br J Cancer. 2003. PMID: 12698177 Free PMC article.

6

Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.

Pföhler C, Cree IA, Ugurel S, Kuwert C, Haass N, Neuber K, Hengge U, Corrie PG, Zutt M, Tilgen W, Reinhold U. Pföhler C, et al. Among authors: ugurel s. Anticancer Drugs. 2003 Jun;14(5):337-40. doi: 10.1097/00001813-200306000-00002. Anticancer Drugs. 2003. PMID: 12782938 Clinical Trial.

7

Systemic treatment in advanced melanoma: innovative perspectives.

Ugurel S, Schadendorf D. Ugurel S, et al. Onkologie. 2003 Jun;26(3):234-8. doi: 10.1159/000071618. Onkologie. 2003. PMID: 12845207 Review.

8

Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients.

Ugurel S, Uhlig D, Pföhler C, Tilgen W, Schadendorf D, Reinhold U. Ugurel S, et al. Cancer Immunol Immunother. 2004 Jun;53(6):551-9. doi: 10.1007/s00262-003-0489-1. Epub 2004 Jan 16. Cancer Immunol Immunother. 2004. PMID: 14727087 Free PMC article.

9

[Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].

Pföhler C, Steinhäuser S, Wagner A, Ugurel S, Tilgen W. Pföhler C, et al. Among authors: ugurel s. Hautarzt. 2004 Feb;55(2):171-5. doi: 10.1007/s00105-003-0620-4. Hautarzt. 2004. PMID: 14968328 German.

10

Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

Ugurel S, Lindemann M, Schadendorf D, Grosse-Wilde H. Ugurel S, et al. Cancer Immunol Immunother. 2004 Nov;53(11):1051. doi: 10.1007/s00262-004-0565-1. Epub 2004 Jun 30. Cancer Immunol Immunother. 2004. PMID: 15232653 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page